Replies to post #6901 on Marker Therapeutics Inc (MRKR)

[ash111]

We have no disagreement.This is main reason for shareholders to keep holding TPIV (and the world wide Patients to have hopes)

http://www.usatoday.com/story/news/nation/2015/02/03/mayo-clinic-triple-negative-breast-cancer-drug-trial/22785941/

[TOB]

I know about TPIV's "potential", how many biotech's did GREAT in phase 1 and then failed down the road? -ADVFN_epigenetics

That's the long-term bet. Right now risk is greatly reduced becaause both Phase1 Clinical Trials had positive primary outcomes.

So, this means later stage Phase 2 clinical trials are highly likely. Generally progressing to P2 means higher share prices, or at least share price support.

No clinical trial can fail at the present, so reduced risk.

Once P2 clinical trials are well underway, I agree that at that point risk increases. My investment thesis is it will likely be possible to take some money off the TPIV table at higher share prices up till that point. Right now looks like too low. JMO that we are seeing a capitulation low. I could be wrong. (I note the chart just turned green)

Of course in hindsight it would have been great to have sold some higher.